Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study

BACKGROUND: Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to determine the efficacy and safety profile of eribulin and explore potential predictive factors for th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Zhao, Yannan, Xie, Ning, Li, Wei, Chen, Wenyan, Lv, Zheng, Zheng, Yabing, Sun, Tao, Liu, Jieqiong, Zhang, Jian, Hu, Shihui, Wang, Yajun, Gong, Chengcheng, Li, Yi, Xie, Yizhao, Ge, Rui, Xu, Fei, Wang, Biyun
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2021
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274129/
https://ncbi.nlm.nih.gov/pubmed/34290830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211030210
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados